Santos, M. E.Ramiro, S.Van der Heijde, D.Landewé, R.Santos, F. PimentelMachado, A. R. CruzFerreira, C.Gomes, C.Soares, C. DantasMiguel, C.Albuquerque, F.Martins, F.Silva, L.Santos, H.Almeida, I.Bernardes, M.Khmelinskii, N.Valente, P.Teixeira, P. M.Matias, S. EmídioFraga, V.Branco, J. C.Sepriano, A.2024-12-202024-12-202024-060392-856Xhttp://hdl.handle.net/10400.1/26536Fourteenth International Congress on SpondyloarthritidesASAS and EULAR recommend the use of an improvement ≥1.1 in ASDAS at 12 weeks to determine the continuation of a bDMARD. However, it is debated whether improvements can occur and whether patients’ characteristics influence (time to) response.engConference object10.1136/annrheumdis-2024-eular.2368